Peking University Shenzhen Hospital
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China68 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD | Deglutition Disorders, Digestive System Diseases, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease | Recruiting | Not applicable | 2026-10-07 | NCT07667894 | |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-30 | NCT07361497 | |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-09-30 | NCT06935357 | |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Recruiting | Phase 3 | 2026-09-29 | NCT06962800 | |
| A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-24 | NCT07477587 | |
| ASPIrin in Reducing Events in Dialysis ( ASPIRED ) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 4 | 2026-09-14 | NCT04381143 | |
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 2 | 2026-09-11 | NCT06706310 | |
| A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-11 | NCT05707377 | |
| Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria | Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | Recruiting | Phase 2 | 2026-09-04 | NCT07512596 | |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04822181 | |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 3 | 2026-08-13 | NCT07168161 | |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT07744256 | |
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) | DNA Virus Infections, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Morphological and Microscopic Findings, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Squamous Intraepithelial Lesions, Tumor Virus Infections, Urogenital Diseases, cervix disorder, dysplasia of cervix, female reproductive system disorder, human papilloma virus infection, infectious disease, neoplasm, precancerous condition, sexually transmitted disease, uterine disorder, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Phase 2 | 2026-07-09 | NCT07669363 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery | Body Temperature Changes, Hypothermia, Hypothermia, Accidental, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Not yet recruiting | Not applicable | 2026-06-23 | NCT07655687 | |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Phase 2 | 2026-06-15 | NCT07647133 | |
| Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-06-11 | NCT07641049 | |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Extrahepatic Cholangiocarcinoma, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, intrahepatic cholangiocarcinoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-11 | NCT07641036 | |
| Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-11 | NCT07641023 | |
| Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, metastatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-04 | NCT07627711 | |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Recruiting | Phase 1 / Phase 2 | 2026-06-04 | NCT07627698 | |
| Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, esophageal adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-06-03 | NCT07622940 | |
| Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Early phase 1 | 2026-06-03 | NCT07504445 | |
| A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-06-03 | NCT07077434 | |
| EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-06-01 | NCT07617805 |